Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer

References

• Nagy JD, Armbruster D. Evolution of uncontrolled proliferation and the angiogenic switch in cancer. Math Biosci Eng. 2012;9(4):843–876.
   PubMed Web of Science ®Google Scholar
• Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC, Yen Y. Cancers in Taiwan: practical insight from epidemiology, treatments, biomarkers, and cost. J Formos Med Assoc. 2020; 119(12):1731–1741.
   PubMed Web of Science ®Google Scholar
• Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol. 2010;6(7):363–370.
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66(6):1192–1308.
   Google Scholar
• Trichopoulos D, Li FP, Hunter DJ. What causes cancer? Sci Am. 1996;275(3):80–87.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590.
   PubMed Web of Science ®Google Scholar
• Schwartz MK. Enzymes in cancer. Clin Chem. 1973;19(1):10–22.
   PubMed Web of Science ®Google Scholar
• Wen KC, Huang RL, Chen LY, Wu TI, Lu CH, Chu TY, Ou YC, Wu CH, Hsu ST, Ding DC, et al. Endometrial cancer detection using a cervical DNA methylation assay (MPap) in women with abnormal uterine bleeding: a multicenter hospital-based validation study. Cancers. 2022;14(17):4343.
   PubMed Web of Science ®Google Scholar
• Voon YC, Omar IS, Wu MH, Said NA, Chung I. Cancer‑associated fibroblasts as cellular vehicles in endometrial cancer cell migration. Oncol Lett. 2022;23(1):1–5.
   PubMed Web of Science ®Google Scholar
• Wu CH, Chen HY, Wang CW, Shieh TM, Huang TC, Lin LC, Wang KL, Hsia SM. Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget. 2016;7(45):73432–73447.
   PubMedGoogle Scholar
• Mohamed MM, Sloane BF. Multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764–775.
   PubMed Web of Science ®Google Scholar
• Chia-Chi Y, Chieh-Yi K, Hsing-Chun T, Ming-Ting C, Meng-Chen T. Consecutive successful pregnancies after conservative management of early stage endometrial carcinoma. Clin Med Rev Case Rep. 2018;5:233.
   Google Scholar
• Yeh CC, Su FH, Tzeng CR, Muo CH, Wang WC. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: a population-based historical cohort study. PLOS One. 2018;13(3):e0194011.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–1159.
   PubMed Web of Science ®Google Scholar
• Liew PL, Huang RL, Wu TI, Liao CC, Chen CW, Su PH, Wang HC, Weng YC, Lai HC. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. Clin Epigenetics. 2019;11(1):170.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Chang CC, Wang YY, Chiang WC, Shih YH, Shieh TM, Wang KL, Ali M, Hsia SM. Adlay testa (Coix lachryma-jobi L. var. ma-yuen Stapf.) ethanolic extract and its active components exert anti-proliferative effects on endometrial cancer cells via cell cycle arrest. Molecules. 2021;26(7):1966.
   PubMed Web of Science ®Google Scholar
• Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, Lai HC. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. J Gynecol Oncol. 2018;29(1):e17.
   PubMed Web of Science ®Google Scholar
• Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2018:1–13.
   Google Scholar
• Kurnianda J, Setiawan SA. Endometrial cancer after tamoxifen-containing adjuvant treatment for breast cancer. Indones J Cancer Control. 2021;1(2):60–66.
   Google Scholar
• Chen HY, Chiang YF, Huang CY, Shieh TM, Kao C, Chang FK, Huang TC, Ali M, Chang HY, Hong YH, et al. Spirulina phycocyanin extract and its active components suppress epithelial-mesenchymal transition process in endometrial cancer via targeting TGF-beta1/SMAD4 signaling pathway. Biomed Pharmacother. 2022; 152:113219.
   PubMed Web of Science ®Google Scholar
• Huang CY, Liao KW, Chou CH, Shrestha S, Yang CD, Chiew MY, Huang HT, Hong HC, Huang SH, Chang TH, et al. Pilot study to establish a novel five-gene biomarker panel for predicting lymph node metastasis in patients with early stage endometrial cancer. Front Oncol. 2019;9:1508.
   PubMed Web of Science ®Google Scholar
• Huang R-L, Su P-H, Liao Y-P, Wu T-I, Hsu Y-T, Lin W-Y, Wang H-C, Weng Y-C, Ou Y-C, Huang TH-M, et al. Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings. Clin Cancer Res. 2017;23(1):263–272.
   PubMed Web of Science ®Google Scholar
• Lin CY, Chao A, Wang TH, Hsueh S, Lee YS, Wu TI, Chao AS, Huang HJ, Chou HH, Chang TC, et al. A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. J Mol Med. 2014;92(9):969–981.
   PubMed Web of Science ®Google Scholar
• Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Gynecol Oncol. 2021;31(1):12–39.
   Google Scholar
• Nepali K, Sharma S, Sharma M, Bedi P, Dhar K. Rational approaches, design strategies, structure-activity relationship, and mechanistic insights for anticancer hybrids. Eur J Med Chem. 2014;77:422–487.
   PubMed Web of Science ®Google Scholar
• Chao MW, Lin TE, HuangFu WC, Chang CD, Tu HJ, Chen LC, Yen SC, Sung TY, Huang WJ, Yang CR, et al. Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach. J Enzyme Inhib Med Chem. 2021;36(1):98–108.
   PubMed Web of Science ®Google Scholar
• Satriyo PB, Yeh CT, Chen JH, Aryandono T, Haryana SM, Chao TY. Dual therapeutic strategy targeting tumor cells and tumor microenvironment in triple-negative breast cancer. J Cancer Res Pract. 2020;7(4):139–148.
   Google Scholar
• Yen SC, Chen LC, Huang HL, HuangFu WC, Chen YY, Lin TE, Lien ST, Tseng HJ, Sung TY, Hsieh JH, et al. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorg Chem. 2022; 121:105675.
   PubMed Web of Science ®Google Scholar
• Chen L-C, Tseng H-J, Liu C-Y, Huang Y-Y, Yen C-C, Weng J-R, Lu Y-L, Hou W-C, Lin TE, Pan I-H, et al. Design of diarylheptanoid derivatives as dual inhibitors against class IIa histone deacetylase and β-amyloid aggregation. Front Pharmacol. 2018; 9:708.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Ray-Coquard I, Joly F. PARP inhibitor in advanced endometrial carcinoma beyond BRCA and related genetic mutations. JCO Precis Oncol. 2020;4(4):1025–1026.
   PubMedGoogle Scholar
• Senguttuvan RN, Wei C, Raoof M, Dellinger TH, Wang EW. Complete pathologic response to PARP inhibitor Olaparib in a patient with stage IVB recurrent endometrioid endometrial adenocarcinoma. J Clin Med. 2023;12(11):3839.
   PubMed Web of Science ®Google Scholar
• You B, Leary A, Rodrigues M, Follana P, Abdeddaim C, Joly F, Bin S, Villeneuve L, Alexandre M, Boutitie F, et al. Abstract CT005: safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial. Cancer Res. 2022;82(12 Suppl):CT005.
   Web of Science ®Google Scholar
• Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, Hosoya N, Koso T, Fukuda T, Inaba K, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014;14(1):179.
   PubMedGoogle Scholar
• Zhang J, Gao Y, Zhang Z, Zhao J, Jia W, Xia C, Wang F, Liu T. Multi-therapies based on PARP inhibition: potential therapeutic approaches for cancer treatment. J Med Chem. 2022;65(24):16099–16127.
   PubMed Web of Science ®Google Scholar
• a) Chambon P, Weill J, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963;11(1):39–43.
   PubMed Web of Science ®Google Scholar
  b) Lai SW, Bamodu OA, Chen JH, Wu AT, Lee WH, Chao TY, Yeh CT. Targeted PARP inhibition combined with FGFR1 blockade is synthetically lethal to malignant cells in patients with pancreatic cancer. Cells. 2020;9(4):911.
   PubMed Web of Science ®Google Scholar
• Benjamin RC, Gill DM. ADP-ribosylation in mammalian cell ghosts. Dependence of poly (ADP-ribose) synthesis on strand breakage in DNA. J Biol Chem. 1980;255(21):10493–10501.
   PubMed Web of Science ®Google Scholar
• Demény MA, Virág L. The PARP enzyme family and the hallmarks of cancer part 1. Cell intrinsic hallmarks. Cancers. 2021;13(9):2042.
   PubMed Web of Science ®Google Scholar
• Sovak M, Chuai S, Anderson S, Barakat R, Dupont J, Hensley M, Sabbatini P, Spriggs D, Aghajanian C. Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: a retrospective study. JCO. 2005;23(16 Suppl):5020–5020.
   Web of Science ®Google Scholar
• Yeh TS, Hsieh RH, Shen SC, Wang SH, Tseng MJ, Shih CM, Lin JJ. Nuclear βII-tubulin associates with the activated notch receptor to modulate notch signaling. Cancer Res. 2004;64(22):8334–8340.
   PubMed Web of Science ®Google Scholar
• Ho CT, Chang YJ, Yang LX, Wei PL, Liu TZ, Liu JJ. A novel microtubule-disrupting agent induces endoplasmic reticular stress-mediated cell death in human hepatocellular carcinoma cells. PLoS One. 2015;10(9):e0136340.
   PubMed Web of Science ®Google Scholar
• Ho ST, Lin CC, Tung YT, Wu JH. Molecular mechanisms underlying yatein-induced cell-cycle arrest and microtubule destabilization in human lung adenocarcinoma cells. Cancers. 2019;11(9):1384.
   PubMed Web of Science ®Google Scholar
• Boone RM, Praiss AM, Huang Y, Melamed A, Khoury-Collado F, Hou JY, Gockley A, Clair CMS, Hershman DL, Wright JD. Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials. Gynecol Oncol. 2023; 169:70–77.
   PubMed Web of Science ®Google Scholar
• Engel JB, Schönhals T, Weidler C, Häusler S, Krockenberger M, Rieger L, Dietl J, Wischhusen J, Honig A. Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. Oncol Rep. 2009;22(2):361–367.
   PubMed Web of Science ®Google Scholar
• Dinkic C, Jahn F, Zygmunt M, Schuetz F, Rom J, Sohn C, Fluhr H. PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncol Lett. 2017;13(4):2847–2851.
   PubMed Web of Science ®Google Scholar
• Zheng L, Ren R, Sun X, Zou Y, Shi Y, Di B, Niu MM. Discovery of a dual tubulin and poly (ADP-ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation. J Med Chem. 2021;64(21):15702–15715.
   PubMed Web of Science ®Google Scholar
• Long H, Hu X, Wang B, Wang Q, Wang R, Liu S, Xiong F, Jiang Z, Zhang XQ, Ye WC, et al. Discovery of novel apigenin–piperazine hybrids as potent and selective poly (ADP-Ribose) polymerase-1 (PARP-1) inhibitors for the treatment of cancer. J Med Chem. 2021;64(16):12089–12108.
   PubMed Web of Science ®Google Scholar
• Su C, Haskins AH, Omata C, Aizawa Y, Kato TA. PARP inhibition by flavonoids induced selective cell killing to BRCA2-deficient cells. Pharmaceuticals. 2017;10(4):80.
   Web of Science ®Google Scholar
• Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA. Natural and glucosyl flavonoids inhibit poly (ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells. Oncol Rep. 2014;31(2):551–556.
   PubMed Web of Science ®Google Scholar
• Geraets L, Moonen HJ, Brauers K, Wouters EF, Bast A, Hageman GJ. Dietary flavones and flavonoles are inhibitors of poly (ADP-ribose) polymerase-1 in pulmonary epithelial cells. J Nutr. 2007;137(10):2190–2195.
   PubMed Web of Science ®Google Scholar
• Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 2000;19(21):5720–5728.
   PubMed Web of Science ®Google Scholar
• Chiu HW, Yeh YL, Ho SY, Wu YH, Wang BJ, Huang WJ, Ho YS, Wang YJ, Chen LC, Tu SH. A new histone deacetylase inhibitor enhances radiation sensitivity through the induction of misfolded protein aggregation and autophagy in triple-negative breast cancer. Cancers (Basel). 2019;11(11):1703.
   PubMed Web of Science ®Google Scholar
• Yu SH, Kao YT, Wu JY, Huang SH, Huang ST, Lee CM, Cheng KT, Lin CM. Inhibition of AMPK-associated autophagy enhances caffeic acid phenethyl ester-induced cell death in C6 glioma cells. Planta Med. 2011;77(9):907–914.
   PubMed Web of Science ®Google Scholar
• Chen RJ, Lee YH, Yeh YL, Wu WS, Ho CT, Li CY, Wang BJ, Wang YJ. Autophagy-inducing effect of pterostilbene: A prospective therapeutic/preventive option for skin diseases. J Food Drug Anal. 2017;25(1):125–133.
   PubMed Web of Science ®Google Scholar
• Su YK, Huang WC, Lee WH, Bamodu OA, Zucha MA, Astuti I, Suwito H, Yeh CT, Lin CM. Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication. Tumour Biol. 2017;39(5):1010428317691689.
   Google Scholar
• Chang CH, Lee CY, Lu CC, Tsai FJ, Hsu YM, Tsao JW, Juan YN, Chiu HY, Yang JS, Wang CC. Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling. Int J Oncol. 2017;50(3):873–882.
   PubMed Web of Science ®Google Scholar
• Lin JF, Tsai TF, Liao PC, Lin YH, Lin YC, Chen HE, Chou KY, Hwang TIS. Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling. Carcinogenesis. 2013;34(2):406–414.
   PubMed Web of Science ®Google Scholar
• Chen MY, Yadav VK, Chu YC, Ong JR, Huang TY, Lee KF, Lee KH, Yeh CT, Lee WH. Hydroxychloroquine (HCQ) modulates autophagy and oxidative DNA damage stress in hepatocellular carcinoma to overcome sorafenib resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 axis. Cancers. 2021;13(13):3227.
   PubMed Web of Science ®Google Scholar
• Lan SH, Lin SC, Wang WC, Yang YC, Lee JC, Lin PW, Chu ML, Lan KY, Zuchini R, Liu HS, et al. Autophagy upregulates miR-449a expression to suppress progression of colorectal cancer. Front Oncol. 2021; 11:738144.
   PubMed Web of Science ®Google Scholar
• Guru SK, Pathania AS, Kumar S, Ramesh D, Kumar M, Rana S, Kumar A, Malik F, Sharma PR, Chandan BK, et al. Secalonic acid-D represses HIF1α/VEGF-mediated angiogenesis by regulating the Akt/mTOR/p70S6K signaling cascade. Cancer Res. 2015;75(14):2886–2896.
   PubMed Web of Science ®Google Scholar
• Pathania AS, Guru SK, Verma M, Sharma C, Abdullah ST, Malik F, Chandra S, Katoch M, Bhushan S. Disruption of the PI3K/AKT/mTOR signaling cascade and induction of apoptosis in HL-60 cells by an essential oil from Monarda citriodora. Food Chem Toxicol. 2013; 62:246–254.
   PubMed Web of Science ®Google Scholar
• Chacko SM, Nevin KG, Dhanyakrishnan R, Kumar BP. Protective effect of p-coumaric acid against doxorubicin induced toxicity in H9c2 cardiomyoblast cell lines. Toxicol Rep. 2015;2:1213–1221.
   PubMedGoogle Scholar
• Berman H, Henrick K, Nakamura H. Announcing the worldwide protein data bank. Nat Struct Biol. 2003;10(12):980–980.
   PubMedGoogle Scholar
• Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automatic docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Computer-Aided Mol Des. 1996;10(4):293–304.
   PubMed Web of Science ®Google Scholar
• Miteva MA, Guyon F, Tufféry P. Frog2: efficient 3D conformation ensemble generator for small compounds. Nucleic Acids Res. 2010;38:W622–W627.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson A. Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function. Effic Optim Multithreading. 2009;31(2):455–461.
   Google Scholar
• Paul Gleeson M, Hersey A, Hannongbua S. In-silico ADME models: a general assessment of their utility in drug discovery applications. Curr Top Med Chem. 2011;11(4):358–381.
   PubMed Web of Science ®Google Scholar
• DeLano WL. Pymol: an open-source molecular graphics tool. CCP4 Newsl Protein Crystallogr. 2002;40(1):82–92.
   Google Scholar
• Cal Ã. Lead profiling lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004; 7:337–341.
   Google Scholar
• Chanda D, Bhushan S, Guru SK, Shanker K, Wani ZA, Rah BA, Luqman S, Mondhe DM, Pal A, Negi AS. Anticancer activity, toxicity and pharmacokinetic profile of an indanone derivative. Eur J Pharm Sci. 2012;47(5):988–995.
   PubMed Web of Science ®Google Scholar